Vascular Protective Effect and Its Possible Mechanism of Action on Selected Active Phytocompounds: A Review

Kamaruddin, Nur Aqilah; Hakim Abdullah, Muhammad Nazrul; Tan, Jun Jie; Lim, Vuanghao; Fong, Lai Yen; Abd Ghafar, Siti Aisyah; Yong, Yoke Keong

doi:https://doi.org/10.1155/2022/3311228

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Conclusion Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Special Issue

Underlying Mechanisms of the Cardioprotective Effects of Natural Products on Endothelial Function and Arteriosclerosis

View this Special Issue

Review Article | Open Access

Volume 2022 | Article ID 3311228 | https://doi.org/10.1155/2022/3311228

Vascular Protective Effect and Its Possible Mechanism of Action on Selected Active Phytocompounds: A Review

Nur Aqilah Kamaruddin,^1,2Muhammad Nazrul Hakim Abdullah,³Jun Jie Tan,⁴Vuanghao Lim,⁴Lai Yen Fong,⁵Siti Aisyah Abd Ghafar,⁶and Yoke Keong Yong¹

Academic Editor: Arquimedes Gasparotto Junior

Received08 Dec 2021

Revised22 Mar 2022

Accepted30 Mar 2022

Published16 Apr 2022

Abstract

Vascular endothelial dysfunction is characterized by an imbalance of vasodilation and vasoconstriction, deficiency of nitric oxide (NO) bioavailability and elevated reactive oxygen species (ROS), and proinflammatory factors. This dysfunction is a key to the early pathological development of major cardiovascular diseases including hypertension, atherosclerosis, and diabetes. Therefore, modulation of the vascular endothelium is considered an important therapeutic strategy to maintain the health of the cardiovascular system. Epidemiological studies have shown that regular consumption of medicinal plants, fruits, and vegetables promotes vascular health, lowering the risk of cardiovascular diseases. This is mainly attributed to the phytochemical compounds contained in these resources. Various databases, including Google Scholar, MEDLINE, PubMed, and the Directory of Open Access Journals, were searched to identify studies demonstrating the vascular protective effects of phytochemical compounds. The literature had revealed abundant data on phytochemical compounds protecting and improving the vascular system. Of the numerous compounds reported, curcumin, resveratrol, cyanidin-3-glucoside, berberine, epigallocatechin-3-gallate, and quercetin are discussed in this review to provide recent information on their vascular protective mechanisms in vivo and in vitro. Phytochemical compounds are promising therapeutic agents for vascular dysfunction due to their antioxidative mechanisms. However, future human studies will be necessary to confirm the clinical effects of these vascular protective mechanisms.

1. Introduction

Epidemiological studies in the last few decades have demonstrated that the consumption of foods containing high levels of flavonoids such as curcumin, resveratrol, cyanidin-3-glucoside, berberine, epigallocatechin-3-gallate, and quercetin was associated with a lower risk of cardiovascular morbidity and mortality [1]. The beneficial effect of these phytocompounds in the cardiovascular system was partly due to direct effects towards the blood vessels and the endothelium. Evidence from cohort studies and pivotal research demonstrated the ability of phytocompounds to constantly modulate vasoprotective factors. These factors regulate the function of the endothelial barrier [2,3]. These compounds show promise in the management of cardiovascular disease.

Cardiovascular disease is a leading cause of mortality globally, with a projected increase in the coming years, hence placing a tremendous strain on the world’s health resources [4]. Poor diet, smoking, obesity, and physical inactivity are among the well-known modifiable risk factors for cardiovascular disease, all of which are conditions associated with inflammation [5]. Inflammatory response plays a crucial role in endothelial cell activation/dysfunction and the pathogenesis of cardiovascular diseases [6]. Therefore, new therapeutic targets are sought to prevent cardiovascular diseases.

Although effective, medications are also associated with adverse effects and cost, as well as challenges with patient compliance [7]. On the other hand, herbal medicine with adequate clinical effectiveness and low toxicity has been used as an alternative to treat diseases [8,9]. Natural compounds such as flavonoids are becoming increasingly popular. They offer a variety of therapeutic benefits, including anti-inflammatory and antioxidizing properties, which are critical in the treatment of cardiovascular disorders [10]. In this paper, a few phytocompounds of interest are reviewed for their vascular endothelial cell protective effects against proinflammatory mediators. These compounds were isolated from natural products such as plants, vegetables, and fruits. In addition, the possible mechanisms by which these compounds can improve vascular endothelial cell integrity were elucidated.

2. The Functions of Vascular Endothelium under Physiological and Pathological Conditions

Endothelial cells of the vascular system line the entire circulatory system from the heart to the tiniest capillaries. The endothelial layer consists of 1 to 6 × 10¹³ cells, covers an area of approximately 1–7 m², and weighs approximately 1 kg in an adult human [11]. The vascular system regulates blood fluidity and fibrosis, vascular tone, angiogenesis, vascular permeability, leukocyte adhesion, and platelet aggregation, all of which are important in maintaining the homeostasis of the cardiovascular system [12]. It is well established that a healthy vascular endothelium is an excellent predictor of cardiovascular health, whereas an aberrant vascular endothelium is invariably associated with a range of cardiovascular illnesses, including hypertension and atherosclerosis [13].

Additionally, endothelial cells form a semipermeable barrier that allows certain substances to pass through between the blood and the vascular wall. A variety of localized chemicals, including nitric oxide (NO), prostacyclin, endothelium-derived hyperpolarizing factor, and endothelin, are secreted by vascular endothelial cells to control the blood vessels [14]. These chemicals dilate blood vessels, promote anti-cell proliferation, are involved in antiagglutination, and reduce blood pressure under physiological conditions. These chemicals also alter endothelium homeostasis in pathological situations such as during hypercholesterolemia, vasoactive amine circulation, infection, and immunological conditions [15].

Endothelial cells also play an important function in blood flow regulation. This function is enhanced by the ability of quiescent endothelial cells to form an active antithrombotic surface that facilitates the flow of plasma and cellular components throughout the vasculature [16]. Endothelial cells generate a prothrombotic and antifibrinolytic milieu in response to perturbations, such as those that may occur during inflammation or high hydrodynamic shear stress [17]. Additionally, the production and absorption of vasoactive endothelial chemicals play a role in blood flow regulation. These chemicals work in a paracrine manner to constrict and dilate particular arterial beds in response to stimuli such as endotoxin [18].

The regulation of vascular tone is another essential function of the endothelium. Healthy endothelial cells help to maintain a balance between vasorelaxing and vasoconstricting factors in the blood. Endothelial cells release various vasoconstrictors such as angiotensin II, endothelin, thromboxane A2, and free radicals, while nitric oxide (NO) and prostacyclin (PGI2) are the most potent vasodilators to retain basal vascular tone. Endothelial cells synthesize these vasodilators in response to bradykinin, thrombin, adenosine triphosphate (ATP), adenosine diphosphate (ADP), and shear stress. Particularly, endothelial-derived NO stimulates the soluble guanylyl cyclase (sGC) pathway in smooth muscle cells which results in a reduction of contraction and vasodilation [14]. Hence, impaired bioavailability of NO is attributed to endothelial dysfunction, which initiates pathological events involving chronic inflammation such as atherosclerosis, hypertension, and diabetes [19].

Furthermore, the endothelium is also essential for coordinating leukocyte trafficking during vascular injuries. Lymphocytes, neutrophils, and monocytes do not adhere to the endothelium in physiological conditions due to the antiadhesive phenotype of endothelial cells. However, stimuli such as proinflammatory cytokines, shear stress, oxidized LDL (ox-LDL), and vasoconstrictors could shift the endothelial cell phenotype to be proadhesive to leukocytes, initiating the recruitment and the subsequent migration to the subendothelial space [20]. Here, the leukocytes develop into macrophages and then foam cells, assisting in the formation and progression of atherosclerotic plaques [21]. This shows that endothelial dysfunction and monocyte-endothelial interactions are critical for atherosclerosis’ start and development.

The development of vascular disease is dependent on the activation of the vascular endothelial cell. The activation increases the expression of proinflammatory mediators, chemokines, and growth factors that enhance ROS formation, inhibit eNOS expression, and decrease NO bioavailability [22], priming the blood vessels to be in a more prothrombotic and proinflammatory state [23,24]. Furthermore, the expression of cells adhesion molecules (CAM) such as E-selectin, vascular CAM-1 (VCAM-1), and intercellular adhesion molecules-1 (ICAM-1) is also upregulated, leading to leukocytes’ recruitment, migration, and infiltration [25]. This mechanism occurs in many inflammatory diseases and induces endothelial cell inflammation and endothelial dysfunction [26]. The endothelial cell will have impaired vascular tone, endothelial-dependent vasodilatation, and redox imbalance as well as increased inflammatory reactions inside the wall of the blood vessel [27] (Figure 1). Proinflammatory mediators or cytokines that cause vascular endothelial cell activation and endothelial dysfunction are listed in Table 1. Identification of endothelial cell-derived inflammatory inducing factors and its underlying mechanisms may be beneficial in preventing the onset of cardiovascular diseases.

3. Vascular Protective Effects of Active Phytocompounds

3.1. Curcumin

Curcumin, a flavonoid compound derived from the roots of the plant Curcuma longa, is a major component of turmeric. Turmeric is commonly a spice and food-coloring agent. Curcumin’s ß-diketone group, carbon-carbon double bonds, and phenyl rings with numerous hydroxyl groups and methoxy substituents make it a strong antioxidant [46]. Curcumin also has anti-inflammatory [47], antiviral, antibacterial, antifungal [48], anticancer, and antitumor effects [47,49], making it a promising phytochemical for treating cancer, diabetes, allergies, arthritis, Alzheimer’s disease, and other chronic conditions [50,51].

Curcumin may also help protect endothelial cells from the negative vascular effects stimulated by TNF-α which modulates p38, signal transducer and activator of transcription-3 (STAT-3), nuclear factor kappa B (NF-κB), and c-Jun N-terminal kinase (JNK) in endothelial cells [52]. Lee et al. [53] also report that curcumin significantly inhibited TNF-α-induced lectin-like oxidized LDL receptor-1 (LOX-1) expression and suppressed endothelial activation and dysfunction against TNF-α. Specifically, the authors demonstrated that curcumin treatment inhibited the formation of ROS, along with the degradation of IκBα and the translocation of NF-B. Curcumin also simultaneously induced eNOS to ensure sufficient production and availability of NO for optimal endothelial function were not adversely affected [53]. Kim et al. [52] additionally found that curcumin reduced the production of ICAM-1 mRNA and its associated TNF-α-activated protein in human umbilical vein endothelial cells (HUVECs).

One of the prominent effects of curcumin on the endothelium is the inhibition of leukocyte adhesion. An in vitro study has shown that human umbilical vein endothelial cells (HUVECs) pretreated with 40 μM curcumin for 1h completely inhibited endothelial cell adhesion to monocytes. The effect was induced by tumor necrosis factor-alpha (TNF-α) [52,54] and associated with the suppression of cell surface molecules. Particularly, ICAM-1, VCAM-1, E-selectin [54], monocyte chemoattractant protein (MCP)-1, and interleukin (IL)-8 were suppressed by curcumin at both the mRNA and protein level [52]. Leukocyte recruitment and adhesion are inflammatory hallmarks in the vasculature and probably the first stage in atherosclerotic plaque development [55]. Leukocytes adhered to the endothelial cells then differentiate into tissue macrophages, resulting in the development and stabilization of local inflammation. The matured macrophages, as well as their transition into foam cells, eventually form plaque. Hence, the vascular protective effect exhibited by curcumin is derived from the compound’s ability to prevent leukocytes’ recruitment, modulate lipoprotein composition, and attenuate oxidative stress through antioxidative processes.

Another factor that increases the risk of cardiovascular morbidity and mortality is environmental pollutants. [56]. For instance, the presence of high bisphenol A levels in urine and serum is associated with an increased risk and atherogenic alterations in the carotid artery, respectively [57]. Di-(2-ethylhexyl) phthalate (DEHP), on the other hand, is a popular plasticizer used in flexible polyvinyl chloride goods including soft-squeeze toys, food packaging, clothes, medical tubing, and blood storage bags. A growing body of epidemiological research indicates a favourable relationship between circulating levels of phthalate metabolites and cardiovascular diseases [58]. DEHP promoted atherosclerosis in mice model [59] and may enhance the expression of inflammatory mediators such as ICAM-1 and IL-8 in HUVECs via ERK and p38 MAPK signaling pathway. Increase in these markers increases the likelihood of allergic inflammatory reactions leading to hospitalization [60]. Interestingly, the same study reported that curcumin significantly inhibited ICAM-1 and IL-8 production stimulated by DEHP.

Extensive studies indicate that ambient exposure to environmental pollution is strongly associated with an increased risk of cardiovascular morbidity and mortality [56]. For instance, the presence of high urine bisphenol A levels relates to an increased risk of cardiovascular disease, and the elevated serum bisphenol A level is associated with atherogenic alterations in the carotid artery [57]. Di-(2-ethylhexyl) phthalate (DEHP), considered as one of the common environmental pollutants, is a popular plasticizer used in flexible polyvinyl chloride goods including soft-squeeze toys, food packaging, clothes, medical tubing, and blood storage bags. A growing body of epidemiological research indicates a favourable relationship between circulating levels of phthalate metabolites and cardiovascular diseases [58]. DEHP not only promoted atherosclerosis in mice model [59], study from in vitro also found that it may enhance inflammatory mediator expressions such as ICAM-1 and IL-8 in HUVECs via ERK and p38 MAPK signaling pathway, which increases the likelihood of allergic inflammatory reaction admissions [60]. Interestingly, Wang and Dong [60] reported that curcumin significantly inhibited ICAM-1 and IL-8 production which was stimulated by DEHP in the same study.

Pathogens have also been associated with disrupting the normal function of endothelial cells. Lipopolysaccharide (LPS) of Gram-negative bacteria cell walls is also a powerful monocyte/macrophages activator. The activation alters the production of important mediators including inflammatory cytokines and chemokines, leading to acute inflammation in many cell types including endothelial cells [61]. Furthermore, LPS-mediated release of high-mobility group box-1 (HMGB1) from macrophages and dendritic cells plays an important role in vascular inflammation [62,63]. A study revealed that curcumin inhibits LPS-mediated release of HMGB1 and HMGB1-mediated proinflammatory responses in human endothelial cells through downregulation of the cell surface expression of HMGB1 receptors TLR2 and TLR4 [64].

Curcumin injection has also been shown to reduce ICAM-1 expression using a mouse model of lung damage. The compound inhibited neutrophil sequestration by inhibiting the activation of endothelial-derived ICAM-1, which is normally observed in an endotoxemia mice model with induction of heme oxygenase (HO-1) [65]. Boola and colleagues [66] have shown that curcumin therapy for 6 weeks in male renovascular hypertensive rats inhibited the development of hypertension by reducing endothelial dysfunction, vascular remodeling, and oxidative stress. It has also been discovered that curcumin as a daily diet increases antioxidant activity, NO bioavailability, and decreases angiotensin-converting enzyme (ACE) and metalloproteinase-2 (MMP2) and MMP9 expression [66]. Curcumin supplementation at 300 mg/kg body weight reduced diabetic vascular inflammation in diabetes-induced endothelial dysfunction male Wistar rats [67]. The production of both ICAM-1 and the pro-oxidative NOX-2 enzymes was achieved by a reduction in ROS generation and leukocyte/endothelium interaction [67].

Moreover, in stroke-prone spontaneously hypertensive rats (SHRsp), treatment of curcumin at 100 mg/kg/day significantly delayed the onset of stroke and increased survival. These effects were a result of decreased ROS and improved endothelial-dependent relaxation of carotid arteries. In this study, both curcumin-mediated decrease of ROS and increase of NO production were blocked in the presence of UCP2 inhibitor genipin. This result was consistent with the in vitro study in which curcumin increased NO levels and decreased ROS levels in the HUVECs [68].

3.2. Resveratrol

Resveratrol (trans-3, 4, 5-trihydroxystilbene), a natural polyphenolic compound, is abundantly found in grape skin, peanuts, mulberries, and red wine. It is a phytoalexin that plants employ to protect themselves against fungus and other types of aggression. Epidemiological research connecting red wine to decreased mortality from cardiovascular diseases in the French population despite the high intake of dietary cholesterol and saturated fats was later associated with resveratrol [69]. Resveratrol has antioxidative, modulatory lipoprotein metabolism, antiplatelet aggregatory, anti-inflammatory, and antitumor properties [70–72]. Resveratrol also protected the cardiovascular system in a multidimensional way, including vasculature. The protective effect of resveratrol against vascular dysfunction has been demonstrated in in vitro and in vivo studies.

Human coronary artery endothelial cells treated with resveratrol significantly suppressed reactive oxygen species (ROS) production and NF-κB activation while concurrently downregulated the ICAM-1, iNOS, IL-6, and TNF-α inflammatory markers against induction from TNF-α and cigarette smoke extract [73,74]. Resveratrol also protects vascular inflammation by targeting cyclooxygenease-1 (COX-1) and cyclooxygenase-2 (COX-2) that also reduces prostaglandin activity [71]. COX-1 is a constitutive isoform of COX regularly secreted in different sites including vasculature while COX-2 is an inducible isoform that releases prostaglandins, prostacyclines, and thromboxane, all of which cause inflammation [75]. In healthy blood vessels, endothelial and smooth muscle cells express COX-1, with COX-2 a distant second. However, in endothelial cells of both healthy and diseased blood vessels, COX-1 is a significant source of prostaglandins [76]. Overproduction of prostaglandins leads to the formation of prostaglandin D₂ and E₂, prostacyclin, and thromboxane A₂ which eventually promote vascular inflammation and platelet aggregation [76]. Thus, the suppression of COX-1, COX-2, prostaglandin activity, and other inflammatory mediators by resveratrol protects vasculature from phlogistic agent-induced damage. Another study has also shown that resveratrol activates anti-inflammatory pathways, including sirtuin 1, [69] while in vitro studies demonstrated the compound’s antioxidant potential.

Resveratrol reduces ROS generation by inhibiting nicotinamide adenine dinucleotide phosphate oxidases and scavenges hydroxyl, superoxide, metal-induced radicals, and hydrogen peroxide [77–80]. A study by Chen and team [81] demonstrated that high-glucose-induced oxidative stress and apoptosis in murine brain microvascular endothelial cell bEnd3 through the NF-κB/NADPH oxidase/ROS pathway was significantly abrogated by resveratrol treatment. Resveratrol also attenuated oxidative injury in human vascular endothelial cells through the regulation of mtROS homeostasis, which in part was mediated through the activation of the SIRT3 signaling pathway [82]. Although resveratrol was capable to counter oxidative stress-induced vascular injury, the vascular protective effects are likely attributed to the indirect upregulation of the endogenous cellular antioxidant systems rather than its direct ROS scavenging activity. Additionally, resveratrol causes the increase of endogenous antioxidant enzymes in endothelial cells, including superoxide dismutases (SOD) [83], SOD1, glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (NO×4) [84], thioredoxin-1 (Trx-1) [85], heme oxygenase-1 [86], and NAD(P)H:quinone oxidoreductase (NQO1 and NQO2) [87].

Apart from abovementioned mechanism, resveratrol was also reported to protect the vascular system via the antiapoptotic effect. Specifically, resveratrol prevented circulating endothelial cells from oxLDL-induced apoptotic insults by downregulating Lox-1-mediated activation of the Bax-mitochondria-cytochrome c-caspase protease pathway [88], and increasing the expression of endothelial nitric oxide synthase (eNOS), which results in increased nitric oxide generation from endothelial cells [89]. Increased endothelial nitric oxide production can improve endothelial function and acutely reduce systolic blood pressure, which may be critical in preventing cardiovascular disease [90].

The vascular protective effect of resveratrol in animal models is also well documented. Male Wistar rats treated with 50 mg/L of resveratrol for 10 weeks significantly prevented high-fructose corn syrup-induced vascular dysfunction associated with a metabolic syndrome [91]. In addition to insulin resistance, hypertriglyceridemia, and hepatic steatosis, rats on a high-fructose diet also developed endothelial dysfunction [92]. The related mechanisms are decrease in nitric oxide synthase (NOS) activity and increase in ROS generation mediated by the vascular renin angiotensin system, which possibly results in lower NO bioavailability [92]. Resveratrol also significantly mitigated high-fat diet-induced vascular dysfunction in male C57BL/6 mice [93]. As obesity has a strong link with insulin resistance [94], insulin signal loss in endothelial cells promotes leukocyte-endothelial cell interactions, triggering inflammation associated with the development of vascular dysfunction [95]. The vascular protective effect of resveratrol in both metabolic disorders might be attributed to the increased expression of the eNOS and SIRT1 protein [91,93]. Moreover, resveratrol also promoted the integrity of epithelial cell lining, as well as suppressed leukocyte extravasation, which eventually prevented injury of the vascular [93].

3.3. Cyanidin-3-Glucoside (C3G)

Anthocyanins are polyphenols of the flavonoid family, a natural pigment responsible for the blue, purple, red, and orange colours widely present in fruits and vegetables. Anthocyanins are claimed to have potential health-promoting effects. In recent decades, the relatively high intake of anthocyanins is investigated for roles in health promotion and illness prevention. Cyanidin-3-glucoside (C3G), one of the major components of anthocyanins commonly found in black currant, red cabbages, red raspberry, blueberry, blackberry, and purple rice bran, contributes to the violet, blue, and red colours [96]. In vitro and in vivo studies demonstrated the antioxidant and anti-inflammatory properties of C3G [97,98], as well as providing protection against endothelial dysfunction, vascular failure, and myocardium damage [99,100]. It also has been shown to prevent obesity and hyperglycemia [101] and appear to help prevent cardiovascular diseases [102]. C3G and its phenolic metabolites also exhibited distinct biological properties and potentially beneficial effects in various human pathologies [103]. The vascular protective effect of C3G was mainly reported in cell culture models.

Sivasinprasasn et al. [104] and Pantan et al. [105] evaluated the effect of C3G on vascular endothelial cells (EA.hy926) and human aortic vascular smooth muscle cells (HASMCs) in an inflammation model against angiotensin II. Both studies reported that C3G pretreatment significantly suppressed NF-kB signaling pathway through downregulation of NF-kB p65, decreased the expression of inducible nitric oxide synthase (iNOS), enhanced nuclear erythroid-related factor 2 (Nrf2), increased superoxide dismutase (SOD), and increased heme oxygenase (HO-1) activities [104,105]. Pantan and team further investigated the possible vascular protective effect of C3G on angiotensin II-induced human aortic smooth muscle cells (HASMCs) inflammation. C3G significantly suppressed angiotensin II-induced HASMCs proliferation and migration through MAPK and PI3K/Akt pathways [106]. Furthermore, a combination of low-dose statins and C3G possessed a synergistic effect on inhibiting angiotensin II-induced inflammation in vascular smooth muscle cells [105,106]. A combination of atorvastatin and C3G successfully decreased the expression of ICAM-1 and VCAM-1, nitric oxide (NO) production, and NOX1 while concurrently increased NAD(P)H:quinone oxidoreductase (NQO-1) and glutamate-cysteine ligase catalytic subunit (γ-GCLC) [106].

Inflammation and oxidative stress-induced vascular endothelial dysfunction and phenotypic switch of vascular smooth muscle cells are the main factors contributing to the early stage of atherosclerosis [107,108]. Atherosclerosis is established to be a vascular inflammatory disease. Lesion areas in the vascular smooth muscle cells exhibited increased permeability, leukocytes’ migration, foam cells’ formation, and release of proinflammatory cytokines, which trigger a deleterious event such as myocardial infarction [109]. Vascular smooth muscle cells’ proliferation and migration are also triggered by angiotensin II which promotes the formation of reactive oxygen species (ROS) by activating NADH/NADPH and subsequent activation of the NF-kB signaling pathway [110,111], leading to vascular dysfunction. Furthermore, angiotensin II promoted cellular hypertrophy, induced the release of various growth factors, altered the extracellular environment by modifying the matrix composition, and stimulated apoptosis in vascular smooth muscle cells [112]. Thus, the ability of C3G to suppress angiotensin II potentiates the compound against atherosclerosis.

Studies have also found that C3G modulates anti-inflammation in human umbilical vein endothelial cells’ injury caused by TNF-α and lipopolysaccharide (LPS) both in vitro and in vivo [113,114]. Speciale and team [113] demonstrated that pretreatment of C3G at 20–40 μM significantly suppressed TNF-α-induced HUVECs injury in a dose-dependent manner. The protective effects were associated with suppression of adhesion molecules expression, leukocyte adhesion, and antioxidative stress via the NF-kB signaling pathway. C3G also prevented oxidative stress, enhanced the endogenous antioxidant system, and activated the NrF2/ARE signaling pathway [115]. In addition, C3G inhibited vascular smooth muscle cells’ proliferation through the repression of NOX activator 1, which is associated with the involvement of the STAT3 signaling induced by TNF-α [116]. Ma et al. [114] demonstrated that C3G positively reversed the effects of LPS by inhibiting NF-κB and MAPK pathways on HUVECs and in mice models. The vascular protective effects of C3G were also documented against different types of vascular damaging factors, including peroxynitrite [99] and palmitate [117,118]. These studies demonstrate that C3G exhibited vascular protective effects through antioxidant activities by directly or indirectly blocking oxidative stress and enhancing the endogenous antioxidant system.

More recent study by Wang and his team [119] demonstrated the vascular protective effect of C3G in high-fat diet plus balloon catheter injured rabbit model. Based on the data obtained, C3G improved the function of endothelial cells and suppressed blood lipids. In this experiment, C3G may have downregulated miR-204-5p, which led to the upregulation of sirtuin 1 (SIRT1) and the restoration of endothelial cell functions [119]. In addition to this, mice supplemented with C3G significantly reversed hypercholesterolemia-induced endothelial dysfunction in both prevention and intervention studies [120]. Data from the animal studies fully supported the hypothesis from previous in vitro studies. The data suggested that the C3G reduces cholesterol and 7-oxysterol levels through the ATP binding cassette subfamily G member 1 (ABCG1) pathway, lowering superoxide generation and increasing eNOS activity and NO bioavailability, therefore alleviating hypercholesterolemia-induced endothelial dysfunction and atherosclerosis [120].

3.4. Berberine

Berberine (BBR), or 5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo [5,6-á] quinolizinium, is an isoquinoline alkaloid mainly found in rhizomes, roots, and stem bulk of plants such as the Berberidaceae and Ranunculaceae families, and Chinese herb Huanglian. Based on the chemical formula of BBR, C₂₀H₁₈NO₄ is a protozoan morphinane alkaloid [121]. It has long been used in the treatment of gastrointestinal infections and diarrhoea but more recently is reported to be used in treating cardiovascular complications [122]. BBR has been extensively studied on its pharmacological activity in vivo and in vitro settings, in which it exhibited anticancer [123], anti-inflammatory [124], antileishmanial [125], anti-human immunodeficiency virus [126], and neuroprotective agent [127]. Cardiovascular protective effects were revealed based on evidence that BBR suppressed proliferation and migration of vascular smooth muscle cells [128], blocked macrophages-derived foam cell formation [129], anti-inflammatory functions, inactivated inflammasome [130], inhibited platelet activation [131], and normalized vascular endothelial function [132].

BBR treatment also intervened oxidized low-density lipoprotein (oxLDL)-stimulated endothelial dysfunction. oxLDL is a proatherogenic lipoprotein that leads to excessive or abnormal proliferation of vascular endothelial cells eventually leading to atherosclerotic plaque formation [133]. Hsieh and his team [132] documented that BBR perturbed ROS production triggered by oxLDL on HUVECs. Moreover, BBR protected the HUVECs by reducing cytotoxicity and apoptosis induced by oxLDL. This effect was attributed to the regulation of mitochondrial transmembrane permeability, reducing proapoptotic protein while increasing antiapoptotic proteins [132]. Xu et al. [134] further reported that the antiproliferative and anti-inflammatory activities of BBR were exerted by lowering the expression of NF-кB, lectin-like oxidized low-density lipoprotein (LDL) receptor-1 (LOX-1), proliferating cell nuclear antigen (PCNA), and inhibiting the phosphorylation of the PI3K/Akt, extracellular signal-regulated protein kinase (ERK1/2), and p38 mitogen-activated protein kinases (MAPKs) on HUVECs, as stimulated by oxLDL.

Similar to other proinflammatory cytokines, oxLDL is capable of activating vascular endothelial cells and subsequently the expression of a series of adhesion molecules, which leads to leukocyte migration and adhesion [135]. HUVECs were also reported to be protected by BBR when challenged with oxLDL through the inhibition of VCAM-1 and ICAM-1 expression and adhesion of monocytes [136]. Interaction between oxLDL with its scavenger receptor, the lectin-like oxLDL receptor 1 (LOX1), was shown to stimulate endothelial expression and secretion of proatherogenic enzymes as well as the production of NOX (nicotinamide adenine dinucleotide oxidase)-derived ROS, thereby decreasing local NO level [137]. Interestingly, BBR suppressed LOX1 expression in the HUVECs through counterreaction with NOX2-derived ROS, MAPK/Erk1/2, and NF-κB activation [138]. More surprisingly, BBR exhibited higher activity compared to that of the reference drug, lovastatin [138].

Studies have also revealed that BBR effectively inhibited inflammatory effects caused by TNF-α in cultured human aortic endothelial cells (HAECs) and HUVECs [138,139]. BBR could prevent TNF-α-induced LOX1 expression and oxidative stress, possibly through the NOX, MAPK/Erk1/2, and NF-κB signaling cascade [138]. BBR was shown to abrogate the vascular endothelial damaging effect of TNF-α by attenuating the production of ICAM-1 and MCP-1 through suppression of NF-κB following AMPK activation in the HAECs [139]. BBR also significantly reverted vascular endothelial cell injury caused by other damaging factors. For instance, BBR suppressed leukocyte adhesion and expression of adhesion molecules in both in vivo and in vitro endothelial cell models. In these models, the damage was induced by LPS via blocking the NF-κB signaling pathway [140].

BBR protected vascular endothelial cells against angiotensin II by reducing intracellular ROS production, MCP-1, and monocyte adhesion [141]. In addition, BBR was also capable of enhancing NO production in vascular endothelial cells via upregulation of eNOS expression and its activity, in which the underlying mechanism might involve upregulation of AMP-activated protein kinase (AMPK) and downregulation of NOX4 activities [142]. Furthermore, Cheng and his team [143] revealed the vascular endothelial protective effect of BBR via a clinical trial and in vitro model. According to the data, BBR significantly reduced serum malondialdehyde (MDA) level and circulating endothelial microparticles in human sample, which were correlated with improvement of flow-mediated vasodilation [143]. Moreover, CD31+/CD42 circulating endothelial microparticles have emerged as a sensitive marker for endothelial damage in response to a variety of stimuli, including inflammation, partially via increasing oxidative stress in endothelial cells [144,145]. In a cell culture setting, BBR also significantly reversed the vascular endothelial injury caused by endothelial microparticles, by altering the oxidative stress level [143].

3.5. Epigallocatechin-3-Gallate

Green tea (Camellia sinensis), a beverage widely diffused and consumed in the Asian population, has long been known for its extensive health benefits, which are mainly attributed to its polyphenol content [146]. In fresh leaf in dry weight, approximately 30% is made up of polyphenol contents, particularly flavanols and flavonols [147]. Catechins are the major flavonoids found in green tea [147], and among the catechins, epigallocatechin-3-gallate (EGCG) is mainly present in green tea. Extensive research has revealed that EGCG exhibited antioxidative stress [148], anti-inflammation [149], anticancer [150,151], antimicrobial [152], neuroprotective [153], hepatoprotective [154], renal protective [155], and cardiovascular protective effects [156].

The phenol rings in EGCG’s structure trap electrons and scavengers’ free radicals [157], conferring the capability to inhibit the formation of ROS, and consequently the harming effects of oxidative stress [158]. EGCG had also effectively suppressed platelet activation induced by collagen or thrombin [159] and improved the function of mitochondria [160]. However, studies have shown that EGCG at high concentrations can cause self-oxidization and function as a prooxidant [161,162]. This occurs via the production of hydroxyl radicals, hydrogen peroxide, and quinonoid intermediates which can cause cytotoxicity [163]. Therefore, more evidence is required to evaluate the relationship between dose and antioxidant signaling pathways in cellular activity.

The vascular protective effect of EGCG was observed in a TNF-α-induced inflammation cell culture study with HUVECs. EGCG significantly reduced MCP-1 and monocyte adhesion in a dose-dependent manner via inhibition of NF-κB signaling cascade against [164]. Furthermore, Yang and team demonstrated that EGCG suppressed the inflammatory response of vascular endothelial cells by increasing the cytosolic calcium (Ca²⁺) triggered by TNF-α [165]. Elevation of cytosolic Ca²⁺ causes the activation of disintegrin and cleavage of metalloprotease 10 (ADAM10), followed by ectodomain shedding of tumor necrosis factor receptor 1 (TNFR1) [165]. By decreasing the number of receptors on the endothelial cell surface, the shedding of TNFR1 ectodomain reduces the cell’s sensitivity towards TNF-α. Furthermore, the released ectodomain part of TNFR1 may bind to TNF-α in the extracellular space and negate its action [166]. A study revealed that EGCG potentially suppressed the inflammatory response of vascular endothelial cells against TNF-α via ADAM-mediated ectodomain shedding of TNFR1 [167]. Moreover, treatment of EGCG on human coronary artery endothelial cells caused the downregulation of multiple cytokines, chemokines, and transcription factor activity, including NF-κB-p65 DNA-binding activity, MCP1, IL-6, and IL-8 stimulated by TNF-α [168]. Moreover, EGCG also significantly reversed endothelial hyperpermeability and monocytes stimulated by TNF-α [168].

The treatment of HUVECs with EGCG caused a reduction of oxidative stress factors including ROS, nitrite, and MDA, while concurrently enhancing the SOD and GSH antioxidant enzymes [169]. EGCG significantly prevented HUVECs apoptosis and expression of adhesion molecules by inhibiting NF-κB activation [169]. A study has additionally shown that EGCG abrogated MC-LR-induced apoptosis of HUVECs through activation of NRF2/HO-1 signaling [170]. Microcystin-LR (MC-LR) is a toxin released from aquatic cyanobacteria and causes a variety of adverse effects on different cell types, tissues, and organs, including liver [171], kidney [172], cardiovascular, lung, intestine, and spleen [173]. MC-LR has also been shown to cause apoptosis in HUVECs by inducing oxidative stress via NF-κB activation [174]. EGCG counteracted NADPH oxidase, particularly p47^phox, in which this angiotensin II-mediated oxidase was responsible to initiate and develop inflammatory vascular diseases and inhibited the expression of iNOS induced by angiotensin II in HUVECs [175,176]. However, EGCG failed to suppress ROS in angiotensin II-stimulated HUVECs [175,176]. EGCG has also been reported to effectively protect vascular endothelial function from high-glucose stress-induced injury [177].

In addition to vascular protective effects in the in vitro models, EGCG also ameliorated endothelial dysfunction in animal models. For instance, Potenza and team evaluated the impact of EGCG administration on the ability of spontaneously hypertensive rats (model of metabolic syndrome with hypertension, insulin resistance, and overweight) to enhance both their cardiovascular and metabolic performances at the same time [178]. Here, EGCG exhibited a vasodilator effect in mesenteric vascular beds ex vivo, in both acute and chronic studies. The study suggested that the vasodilator effect was in part attributed to the stimulation of nitric oxide production from the endothelium through the PI 3-kinase-dependent pathway [178]. Furthermore, obese mice fed with EGCG at 50 mg/kg/day for 10 weeks showed improved insulin sensitivity, glucose tolerance, and endothelial function [177]. As obesity is highly associated with various metabolic and cardiovascular disorders, including insulin resistance, diabetes, and atherosclerosis [179], the pathogenesis of diabetes and its associated cardiovascular consequences is heavily influenced by reciprocal interactions between insulin resistance and endothelial dysfunction [180]. Thus, altering high-fed-diet-induced inflammatory response in obese mice, especially the amelioration of insulin resistance by EGCG, might be beneficial for endothelial function.

3.6. Quercetin

Quercetin (3,3′,4′,5,7 pentahydroxy flavone) is a natural flavonoid widely and abundantly found in almost all plant food such as tea, onion, lettuce, broccoli, beans, fruits, and buckwheat. It is also one of the effective components of ginkgo leaves, mulberry parasitic, sandalwood, and other Chinese herbs [181]. Accumulating evidence suggests that quercetin exhibits antioxidant, anti-inflammatory, and antimicrobial activities [182,183]. Moreover, recent studies have found that quercetin can restrain the proliferation and metastasis of multiple cancer cell types such as breast cancer and colon cancer [181]. The presence of five hydroxyl groups in the structure of quercetin confers a significant level of antioxidant activity. Furthermore, the pyrocatechol type of the benzene ring makes it a strong scavenger of free radicals [184]. Quercetin is one of the most often consumed members of the flavonoid family, accounting for around 65–75% of our daily intake of flavonoids [185]. Quercetin may be found in nature in the form of ramifications that attach to glucose and rutinose [186]. Once consumed, quercetin can be swiftly degraded by the glucosidase enzyme in the digestive system, making it simpler for absorption by the mucosa of the large intestine and subsequently transported to the entire body through the portal circulation [187]. Quercetin is nontoxic and nonlethal to animals, even at large dosages (4000 mg/day), making it a safe supplement for human use [188].

Quercetin protects vascular endothelial injury through multiple approaches, for instance through its antioxidative effects. Treatment of quercetin protected the vascular endothelial cells by scavenging ROS, increasing the level of SOD and HO-1, while concurrently decreasing MDA and XO-1 levels in TNF-α and homocysteine-induced vascular endothelial cells [189,190]. Moreover, quercetin significantly opposed tunicamycin-induced HUVECs injury by reducing endoplasmic reticulum stress, possibly through the poly (ADP-ribose) polymerase (PARP) signaling [191].

Quercetin also demonstrated encouraging benefits for vascular endothelial cells’ dysfunction and endothelial cell activation triggered by diabetes-related high-glucose levels in the circulation. Endothelial cells exposed to a hyperglycemic environment produce less nitric oxide but had increased cell adhesion molecules and inflammatory gene expressions caused by activation of NF-кB signaling [192]. In addition, the hexosamine biosynthesis pathway becomes overactive in diabetic individuals, leading to elevated levels of glucosamine in the blood circulation [193]. Increased glucosamine will cause endoplasmic reticulum stress, which may lead to exacerbation of endothelial cell damage. The damage eventually leads to increased inflammation and lipid metabolic abnormalities, which eventually accelerate the development of atherosclerosis [194]. A study done by Ozyel and the team [192] reported that quercetin was capable of regulating the balance of HUVECs metabolites towards a less inflamed phenotype when challenged with high-glucose stimuli. Furthermore, findings from Cai et al. [195] revealed that quercetin’s protective benefits against high-glucosamine-induced HUVECs damage may be mediated through the ER/CHOP and ER/JNK pathways. PERK may also be a crucial component of the molecular mechanism responsible for these protective effects. More recently, quercetin was shown to inhibit vascular endothelial inflammation in diabetic vasculature, via suppression of myeloperoxidase/high-glucose-dependent hypochlorous acid formation. The acid formation plays an important role in diabetic vascular complications [196].

Quercetin also showed promising data in animal models. Male Sprague-Dawley rats orally treated with quercetin at doses of 25 or 50 mg/kg/day for 6 days significantly ameliorated vascular dysfunction challenged by phenylhydrazine (PHZ) [197]. PHZ is widely used for inducing haemolytic disorders and investigating anemic mechanisms [198]. It is a strong oxidant that exhibits a number of toxic effects, and the free radicals generated from PHZ might directly impact vascular tissues via oxidative stress-induced inflammation and reduction in NO bioactivity, eventually resulting in vascular dysfunction [197]. It is widely known that quercetin possesses a very strong antioxidant activity, capable of scavenging free radicals generated from PHZ and thus decreasing oxidative stress. In addition, quercetin restored arterial blood pressure and vascular responsiveness to endothelium-dependent vasodilators and vasoconstrictors, which ultimately prevent the vascular from PHZ damage [197]. Furthermore, oral administration of quercetin at 50 or 100 mg/kg either prior to or after exposure to LPS protected vascular function as measured by blood pressure, heart rate, and vascular responsiveness, which were all recovered to near-normal levels [199]. These effects were highly associated with upregulation of eNOS expression, a decrease of oxidative stress, and maintenance of the blood GSH redox ratio [199]. Quercetin also reduced inflammatory cardiovascular risk factors, such as serum amyloid A (SAA), C-reactive protein, and fibrinogen levels, when administered to mice fed with an atherogenic 1% cholesterol-containing diet [200]. Quercetin also significantly decreased histological atherosclerotic lesion growth. However, no effect was seen on monocyte adherence to the endothelium and on the lesion macrophage content [200]. The vascular protective effect of quercetin in animal models is mostly similar to other antioxidant compounds, as previously described through antioxidant activities.

4. Conclusion and Future Prospective

Natural herbs are rich sources of potential therapeutic candidates for various diseases including cardiovascular diseases, neurodegenerative disorders, and metabolic dysregulation. Repurposing the existing medications for alternative applications is an important way to discover new therapies with known safety profiles. For cardiovascular diseases, the pivotal components of pathogenesis are ROS production and inflammation, which are targeted by many phytocompounds and existing medications. Although extensive studies have been carried out to determine the vascular protective effects of active phytocompounds reviewed in this paper, there are ongoing developments and research studies on other human diseases. Active phytocompounds isolated from natural resources often face challenges in bioavailability and stability. Thus, improving extraction and formulation techniques to maintain biological activities is crucial. Furthermore, biosafety, long-term bioactivity, degrading properties, interactions with immune cells, the ability to sustainably circulate in humans, and excretion must be thoroughly evaluated before consumption. In addition, further research is needed to minimize the cost of industrial-scale manufacturing, develop better methods for synthesis or extract, and discover the optimal route of administration. New phytochemical agents to treat cardiovascular diseases particularly vascular endothelial cells are expected to surface with the progress of research.

Data Availability

The data sets supporting the conclusions of this study are included within the manuscript.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

Nur Aqilah Kamaruddin was supported by (HLP) Hadiah Latihan Persekutuan from Ministry of Education, Malaysia. The authors wish to thank supporting staff from Anatomy and Histology Laboratory, Physiology Laboratory, and Cell Signaling Laboratory from Faculty of Medicine and Health Sciences, Universiti Putra Malaysia for their excellent technical support. This work was supported by the Ministry of Higher Education, Malaysia, under Fundamental Research Grant Scheme with the code project of FRGS/1/2020/SKK0/UPM/02/1 and reference number under Universiti Putra Malaysia 04-01-20–2271FR.

References

B. H. Parmenter, K. D. Croft, J. M. Hodgson et al., “An overview and update on the epidemiology of flavonoid intake and cardiovascular disease risk,” Food & Function, vol. 11, no. 8, pp. 6777–6806, 2020.
View at: Publisher Site | Google Scholar
C. D. Kay, L. Hooper, P. A. Kroon, E. B. Rimm, and A. Cassidy, “Relative impact of flavonoid composition, dose and structure on vascular function: a systematic review of randomised controlled trials of flavonoid-rich food products,” Molecular Nutrition & Food Research, vol. 56, no. 11, pp. 1605–1616, 2012.
View at: Publisher Site | Google Scholar
D. Zhang, M. Du, Y. Wei, C. Wang, and L. Shen, “A review on the structure–activity relationship of dietary flavonoids for protecting vascular endothelial function: current understanding and future issues,” Journal of Food Biochemistry, vol. 42, no. 5, pp. 1–14, 2018.
View at: Publisher Site | Google Scholar
The Top 10 Causes of Death,” the Top 10 Causes of Death, 2020, https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
M. Z. Allende-Vigo, “Pathophysiologic mechanisms linking adipose tissue and cardiometabolic risk,” Endocrine Practice, vol. 16, no. 4, pp. 692–698, 2010.
View at: Publisher Site | Google Scholar
P. Welsh, G. Grassia, S. Botha, N. Sattar, and P. Maffia, “Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?” British Journal of Pharmacology, vol. 174, no. 22, pp. 3898–3913, 2017.
View at: Publisher Site | Google Scholar
N. Mohebbi, G. Shalviri, M. Salarifar, J. Salamzadeh, and K. Gholami, “Adverse drug reactions induced by cardiovascular drugs in cardiovascular care unit patients,” Pharmacoepidemiology and Drug Safety, vol. 19, no. 9, pp. 889–894, 2010.
View at: Publisher Site | Google Scholar
Y. H. Wu, H. Y. Chen, and C. H. Lai, “Use of Chinese herbal medicine improves chemotherapy-induced thrombocytopenia among gynecological cancer patients: an observational study,” Evidence-based Complementary and Alternative Medicine, vol. 2018, Article ID 4201325, 2018.
View at: Publisher Site | Google Scholar
B.-Y. Lai, A.-J. Chu, B.-W. Yu et al., “Clinical effectiveness and safety of Chinese herbal medicine compound kushen injection as an add-on treatment for breast cancer: a systematic review and meta-analysis,” Evidence-based Complementary and Alternative Medicine, vol. 2022, Article ID 8118408, 16 pages, 2022.
View at: Publisher Site | Google Scholar
K. Yamagata and Y. Yamori, “Inhibition of endothelial dysfunction by dietary flavonoids and preventive effects against cardiovascular disease,” Journal of Cardiovascular Pharmacology, vol. 75, no. 1, pp. 1–9, 2019.
View at: Google Scholar
H. G. Augustin, D. H. Kozian, and R. C. Johnson, “Differentiation of endothelial cells: analysis of the constitutive and activated endothelial cell phenotypes,” BioEssays, vol. 16, no. 12, pp. 901–906, 1994.
View at: Publisher Site | Google Scholar
P. Rajendran, T. Rengarajan, J. Thangavel et al., “The vascular endothelium and human diseases,” International Journal of Biological Sciences, vol. 9, no. 10, pp. 1057–1069, 2013.
View at: Publisher Site | Google Scholar
S. Jamwal and S. Sharma, “Vascular endothelium dysfunction: a conservative target in metabolic disorders,” Inflammation Research, vol. 67, no. 5, pp. 391–405, 2018.
View at: Google Scholar
A. Sandoo, J. J. C. S. Veldhuijzen van Zanten, G. S. Metsios, D. Carroll, and G. D. Kitas, “The endothelium and its role in regulating vascular tone,” The Open Cardiovascular Medicine Journal, vol. 4, no. 1, pp. 302–312, 2015.
View at: Google Scholar
D. H. Endemann and E. L. Schiffrin, “Endothelial dysfunction,” Journal of the American Society of Nephrology, vol. 15, no. 8, pp. 1983–1992, 2004.
View at: Google Scholar
A. Krüger-Genge, A. Blocki, R. P. Franke, and F. Jung, “Vascular endothelial cell biology: an update,” International Journal of Molecular Sciences, vol. 20, no. 18, 2019.
View at: Google Scholar
O. Guipaud, C. Jaillet, K. Clément-Colmou, A. François, and F. Milliat, The Importance of the Vascular Endothelial Barrier in the Immune-Inflammatory Response Induced by Radiotherapy, 2018.
G. Russo, J. A. Leopold, and J. Loscalzo, Vasoactive Substances: Nitric Oxide and Endothelial Dysfunction in Atherosclerosis $.
J. yi Chen, Z. xin Ye, X. fen Wang et al., “Nitric oxide bioavailability dysfunction involves in atherosclerosis,” Biomedicine and Pharmacotherapy, vol. 97, pp. 423–428, 2018.
View at: Google Scholar
M. Félétou and P. M. Vanhoutte, “Endothelium-derived hyperpolarizing factor: where are we now?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 6, pp. 1215–1225, 2006.
View at: Google Scholar
E. J. Baker, M. H. Yusof, P. Yaqoob, E. A. Miles, and P. C. Calder, “Omega-3 fatty acids and leukocyte-endothelium adhesion: novel anti-atherosclerotic actions,” Molecular Aspects of Medicine, vol. 64, pp. 169–181, 2018.
View at: Publisher Site | Google Scholar
H. He, Y. Qiao, Q. Zhou et al., “Iron overload damages the endothelial mitochondria via the ROS/ADMA/DDAHII/eNOS/NO pathway,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 2340392, 19 pages, 2019.
View at: Publisher Site | Google Scholar
C. Park-Windhol and P. A. D'Amore, “Disorders of vascular permeability,” Annual Review of Pathology: Mechanisms of Disease, vol. 11, no. 1, pp. 251–281, 2016.
View at: Publisher Site | Google Scholar
T. C. Baghai, G. Varallo-Bedarida, and C. Born, “Classical risk factors and inflammatory biomarkers: one of the missing biological links between cardiovascular disease and major depressive disorder,” International Journal of Molecular Sciences, vol. 19, no. 6, 2018.
View at: Publisher Site | Google Scholar
D.-H. Zhang, “Tripterine inhibits the expression of adhesion molecules in activated endothelial cells,” Journal of Leukocyte Biology, vol. 80, no. 2, pp. 309–319, 2006.
View at: Publisher Site | Google Scholar
H. J. Sun, Z. Y. Wu, X. W. Nie, and J. S. Bian, “Role of endothelial dysfunction in cardiovascular diseases: the link between inflammation and hydrogen sulfide,” Frontiers in Pharmacology, vol. 10, pp. 1–15, 2020.
View at: Publisher Site | Google Scholar
B. K. Ooi, K. G. Chan, B. H. Goh, and W. H. Yap, “The role of natural products in targeting cardiovascular diseases via Nrf2 pathway: novel molecular mechanisms and therapeutic approaches,” Frontiers in Pharmacology, vol. 9, no. NOV, pp. 1308–1318, 2018.
View at: Publisher Site | Google Scholar
P. Zhou, S. Lu, Y. Luo et al., “Attenuation of TNF-α-induced inflammatory injury in endothelial cells by ginsenoside Rb1 via inhibiting NF-κB, JNK and p38 signaling pathways,” Frontiers in Pharmacology, vol. 8, no. AUG, p. 464, 2017.
View at: Publisher Site | Google Scholar
T. Bian, H. Li, and Q. Zhou, “Human β-defensin 3 reduces TNF-α-induced inflammation and monocyte adhesion in human umbilical vein endothelial cells,” Mediators of Inflammation, vol. 2017, Article ID 8529542, 11 pages, 2017.
View at: Publisher Site | Google Scholar
X. Xie, R. Zhao, and G. Shen, “Impact of cyanidin-3-glucoside on glycated LDL-induced NADPH oxidase activation, mitochondrial dysfunction and cell viability in cultured vascular endothelial cells,” International Journal of Molecular Sciences, vol. 13, no. 12, pp. 15867–15880, 2012.
View at: Publisher Site | Google Scholar
Z. A. Yoke Keong Yong, “Muhd nazrul somchit, “anti-inflammatory properties of bixa orellana leaves extract are associated with suppression of bradykinin-induced endothelial hyperpermeability,” Pharmacognosy Magazine, vol. 14, pp. S352–S357, 2018.
View at: Publisher Site | Google Scholar
E. Terzuoli, S. Meini, P. Cucchi et al., “Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation,” PLoS ONE, vol. 9, no. 1, Article ID e84358, 2014.
View at: Publisher Site | Google Scholar
Y. K. Yong, H. S. Chiong, M. N. Somchit, and Z. Ahmad, “Bixa orellana leaf extract suppresses histamine-induced endothelial hyperpermeability via the PLC-NO-cGMP signaling cascade,” BMC Complementary and Alternative Medicine, vol. 15, no. 1, p. 356, 2015.
View at: Publisher Site | Google Scholar
D. Kugelmann, L. T. Rotkopf, and M. Y. Radeva, “Histamine causes endothelial barrier disruption via Ca2+-mediated RhoA activation and tension at adherens junctions,” Scientific Reports, vol. 8, no. 1, pp. 1–14, 2018.
View at: Publisher Site | Google Scholar
W. D. Ehringer, O.-L. Wang, A. Haq, and F. N. Miller, “Bradykinin and α-thrombin increase human umbilical vein endothelial macromolecular permeability by different mechanisms,” Inflammation, vol. 24, no. 2, pp. 175–193, 2000.
View at: Publisher Site | Google Scholar
C. T. Ng, L. Y. Fong, M. R. Sulaiman et al., “Interferon-gamma increases endothelial permeability by causing activation of p38 MAP kinase and actin cytoskeleton alteration,” Journal of Interferon and Cytokine Research, vol. 35, no. 7, pp. 513–522, 2015.
View at: Publisher Site | Google Scholar
K. Salmeron, T. Aihara, E. Redondo-Castro, E. Pinteaux, and G. Bix, “IL-1alpha induces angiogenesis in brain endothelial cells in vitro: implications for brain angiogenesis after acute injury,” Journal of Neurochemistry, vol. 136, no. 3, pp. 573–580, 2016.
View at: Publisher Site | Google Scholar
L. Du, F. Dong, L. Guo et al., “Interleukin-1β increases permeability and upregulates the expression of vascular endothelial-cadherin in human renal glomerular endothelial cells,” Molecular Medicine Reports, vol. 11, no. 5, pp. 3708–3714, 2015.
View at: Publisher Site | Google Scholar
T. Skaria, J. Burgener, E. Bachli, and G. Schoedon, “IL-4 causes hyperpermeability of vascular endothelial cells through Wnt5A signaling,” PLoS ONE, vol. 11, no. 5, Article ID e0156002, 2016.
View at: Publisher Site | Google Scholar
J. Guo, L. Wang, and L. Wang, “Berberine protects human umbilical vein endothelial cells against LPS-induced apoptosis by blocking JNK-mediated signaling,” Evidence-based Complementary and Alternative Medicine, vol. 2016, Article ID 6983956, 11 pages, 2016.
View at: Publisher Site | Google Scholar
E. Z. Dayang, J. Plantinga, B. ter Ellen, M van Meurs, G Molema, and J Moser, “Identification of LPS-activated endothelial subpopulations with distinct inflammatory phenotypes and regulatory signaling mechanisms,” Frontiers in Immunology, vol. 10, p. 1169, 2019.
View at: Publisher Site | Google Scholar
Y. Liu, X. L. Chen, L. Wang, and M. Martins-Green, “Insulin antagonizes thrombin-induced microvessel leakage,” Journal of Vascular Research, vol. 54, no. 3, pp. 143–155, 2017.
View at: Publisher Site | Google Scholar
M. van der Heijden, G. P. van Nieuw Amerongen, and J. van Bezu, “Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells,” PLoS One, vol. 6, no. 8, 2011.
View at: Publisher Site | Google Scholar
L. Zhang, J. Wang, J. Liang et al., “Propofol prevents human umbilical vein endothelial cell injury from Ang II-induced apoptosis by activating the ACE2-(1-7)-Mas axis and eNOS phosphorylation,” PLoS ONE, vol. 13, no. 7, Article ID e0199373, 2018.
View at: Publisher Site | Google Scholar
X. X. Li, Y. M. Liu, Y. J. Li et al., “High glucose concentration induces endothelial cell proliferation by regulating cyclin‐D2‐related miR‐98,” Journal of Cellular and Molecular Medicine, vol. 20, no. 6, pp. 1159–1169, 2016.
View at: Publisher Site | Google Scholar
E. M. Tanvir, M. S. Hossen, and M. F. Hossain, “Antioxidant properties of popular turmeric (Curcuma longa) varieties from Bangladesh,” Journal of Food Quality, vol. 2017, Article ID 8471785, 8 pages, 2017.
View at: Publisher Site | Google Scholar
A. J. Ruby, G. Kuttan, K. Dinesh Babu, K. N. Rajasekharan, and R. Kuttan, “Anti-tumour and antioxidant activity of natural curcuminoids,” Cancer Letters, vol. 94, no. 1, pp. 79–83, 1995.
View at: Publisher Site | Google Scholar
S. Zorofchian Moghadamtousi, H. Abdul Kadir, and P. Hassandarvish, “A review on antibacterial, antiviral, and antifungal activity of curcumin,” BioMed Research International, vol. 2014, Article ID 186864, 12 pages, 2014.
View at: Publisher Site | Google Scholar
J.-K. Lin, “Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by curcumin,” Archives of Pharmacal Research, vol. 27, no. 7, pp. 683–692, 2004.
View at: Publisher Site | Google Scholar
B. Salehi, Z. Stojanović-Radić, J. Matejić et al., “The therapeutic potential of curcumin: a review of clinical trials,” European Journal of Medicinal Chemistry, vol. 163, pp. 527–545, 2019.
View at: Publisher Site | Google Scholar
S. J. Hewlings and D. S. Kalman, “Curcumin: a review of its effects on human health,” Foods, vol. 6, no. 10, pp. 1–11, 2017.
View at: Publisher Site | Google Scholar
Y. S. Kim, Y. Ahn, M. H. Hong et al., “Curcumin attenuates inflammatory responses of TNF-α-stimulated human endothelial cells,” Journal of Cardiovascular Pharmacology, vol. 50, no. 1, pp. 41–49, 2007.
View at: Publisher Site | Google Scholar
H.-S. Lee, M.-J. Lee, H. Kim et al., “Curcumin inhibits TNFα-induced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 25, no. 5, pp. 720–729, 2010.
View at: Publisher Site | Google Scholar
A. Kumar, S. Dhawan, N. J. Hardegen, and B. B. Aggarwal, “Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-Mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-κb activation,” Biochemical Pharmacology, vol. 55, no. 6, pp. 775–783, 1998.
View at: Publisher Site | Google Scholar
S. Čejková, I. Králová-Lesná, and R. Poledne, “Monocyte adhesion to the endothelium is an initial stage of atherosclerosis development,” Cor et Vasa, vol. 58, no. 4, p. e419, 2016.
View at: Google Scholar
T. Münzel, M. R. Miller, and M. Sørensen, “Reduction of environmental pollutants for prevention of cardiovascular disease: it’s time to act,” European Heart Journal, vol. 41, no. 41, pp. 3989–3997, 2020.
View at: Google Scholar
C. Fang, B. Ning, A. B. Waqar et al., “Bisphenol A exposure enhances atherosclerosis in WHHL rabbits,” PLoS ONE, vol. 9, no. 10, pp. 1–11, 2014.
View at: Publisher Site | Google Scholar
S. Singh and S. S.-L. Li, “Bisphenol A and phthalates exhibit similar toxicogenomics and health effects,” Gene, vol. 494, no. 1, pp. 85–91, 2012.
View at: Publisher Site | Google Scholar
J.-F. Zhao, S.-H. Hsiao, M.-H. Hsu et al., “Di-(2-ethylhexyl) phthalate accelerates atherosclerosis in apolipoprotein E-deficient mice,” Archives of Toxicology, vol. 90, no. 1, pp. 181–190, 2016.
View at: Publisher Site | Google Scholar
J. Wang and S. Dong, “ICAM-1 and IL-8 are expressed by DEHP and suppressed by curcumin through ERK and p38 MAPK in human umbilical vein endothelial cells,” Inflammation, vol. 35, no. 3, pp. 859–870, 2012.
View at: Publisher Site | Google Scholar
M. M. Tucureanu, D. Rebleanu, C. A. Constantinescu et al., “Lipopolysaccharide-induced inflammation in monocytes/macrophages is blocked by liposomal delivery of Gi-protein inhibitor,” International Journal of Nanomedicine, vol. 13, pp. 63–76, 2018.
View at: Publisher Site | Google Scholar
Y. Hirata, H. Kurobe, M. Higashida et al., “HMGB1 plays a critical role in vascular inflammation and lesion formation via toll-like receptor 9,” Atherosclerosis, vol. 231, no. 2, pp. 227–233, 2013.
View at: Publisher Site | Google Scholar
J. Yang, Y. Zhao, P. Zhang et al., “Hemorrhagic shock primes for lung vascular endothelial cell pyroptosis: role in pulmonary inflammation following LPS,” Cell Death & Disease, vol. 7, no. 9, pp. 1–16, 2016.
View at: Publisher Site | Google Scholar
D.-C. Kim, W. Lee, and J.-S. Bae, “Vascular anti-inflammatory effects of curcumin on HMGB1-mediated responses in vitro,” Inflammation Research, vol. 60, no. 12, pp. 1161–1168, 2011.
View at: Publisher Site | Google Scholar
R. Olszanecki, A. Gebska, and R. Korbut, “The role of haem oxygenase-1 in the decrease of endothelial intercellular adhesion molecule-1 expression by curcumin,” Basic and Clinical Pharmacology and Toxicology, vol. 101, no. 6, pp. 411–415, 2007.
View at: Publisher Site | Google Scholar
O. Boonla, U. Kukongviriyapan, P. Pakdeechote et al., “Curcumin improves endothelial dysfunction and vascular remodeling in 2K-1C hypertensive rats by raising nitric oxide availability and reducing oxidative stress,” Nitric Oxide, vol. 42, pp. 44–53, 2014.
View at: Publisher Site | Google Scholar
N. Wongeakin, P. Bhattarakosol, and S. Patumraj, “Molecular mechanisms of curcumin on diabetes-induced endothelial dysfunctions: txnip, ICAM-1, and NOX2 expressions,” BioMed Research International, vol. 2014, Article ID 161346, 14 pages, 2014.
View at: Publisher Site | Google Scholar
C. Lan, X. Chen, Y. Zhang et al., “Curcumin prevents strokes in stroke-prone spontaneously hypertensive rats by improving vascular endothelial function,” BMC Cardiovascular Disorders, vol. 18, no. 1, pp. 43–10, 2018.
View at: Publisher Site | Google Scholar
M. J. Banez, M. I. Geluz, A. Chandra et al., “A systemic review on the antioxidant and anti-inflammatory effects of resveratrol, curcumin, and dietary nitric oxide supplementation on human cardiovascular health,” Nutrition Research, vol. 78, pp. 11–26, 2020.
View at: Publisher Site | Google Scholar
S. Bradamante, L. Barenghi, and A. Villa, “Cardiovascular protective effects of resveratrol,” Cardiovascular Drug Reviews, vol. 22, no. 3, pp. 169–188, 2004.
View at: Publisher Site | Google Scholar
S. Das and D. Das, “Anti-inflammatory responses of resveratrol,” Inflammation and Allergy - Drug Targets, vol. 6, no. 3, pp. 168–173, 2007.
View at: Publisher Site | Google Scholar
B. Tadolini, C. Juliano, L. Piu, F. Franconi, and L. Cabrini, “Resveratrol inhibition of lipid peroxidation,” Free Radical Research, vol. 33, no. 1, pp. 105–114, 2000.
View at: Publisher Site | Google Scholar
A. Csiszar, K. Smith, and N. Labinskyy, “Resveratrol attenuates TNF-α-induced activation of coronary arterial endothelial cells: role of NF-κB inhibition,” American Journal of Physiology - Heart and Circulatory Physiology, vol. 291, no. 4, pp. 1694–1699, 2006.
View at: Publisher Site | Google Scholar
A. Csiszar, N. Labinskyy, A. Podlutsky et al., “Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations,” American Journal of Physiology - Heart and Circulatory Physiology, vol. 294, no. 6, pp. H2721–H2735, 2008.
View at: Publisher Site | Google Scholar
L. A. Abdulkhaleq, M. A. Assi, R. Abdullah, M. Zamri-Saad, Y. H. Taufiq-Yap, and M. N. M. Hezmee, “The crucial roles of inflammatory mediators in inflammation: a review,” Veterinary World, vol. 11, no. 5, pp. 627–635, 2018.
View at: Publisher Site | Google Scholar
M. Félétou, Y. Huang, and P. M. Vanhoutte, “Endothelium-mediated control of vascular tone: COX-1 and COX-2 products,” British Journal of Pharmacology, vol. 164, no. 3, pp. 894–912, 2011.
View at: Publisher Site | Google Scholar
M. Yousefian, N. Shakour, and H. Hosseinzadeh, “The natural phenolic compounds as modulators of NADPH oxidases in hypertension,” Phytomedicine, vol. 55, pp. 200–213, 2019.
View at: Google Scholar
L.-M. Hung, M.-J. Su, W.-K. Chu, C.-W. Chiao, W.-F. Chan, and J.-K. Chen, “The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy,” British Journal of Pharmacology, vol. 135, no. 7, pp. 1627–1633, 2002.
View at: Publisher Site | Google Scholar
S. S. Leonard, C. Xia, B.-H. Jiang et al., “Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses,” Biochemical and Biophysical Research Communications, vol. 309, no. 4, pp. 1017–1026, 2003.
View at: Publisher Site | Google Scholar
Z. Ungvari, Z. Orosz, A. Rivera et al., “Resveratrol increases vascular oxidative stress resistance,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 292, no. 5, pp. H2417–H2424, 2007.
View at: Publisher Site | Google Scholar
F. Chen, L.-H. Qian, B. Deng, Z.-M. Liu, Y. Zhao, and Y.-Y. Le, “Resveratrol protects vascular endothelial cells from high glucose-induced apoptosis through inhibition of nadph oxidase activation-driven oxidative stress,” CNS Neuroscience and Therapeutics, vol. 19, no. 9, pp. 675–681, 2013.
View at: Publisher Site | Google Scholar
X. Zhou, M. Chen, X. Zeng et al., “Resveratrol regulates mitochondrial reactive oxygen species homeostasis through Sirt3 signaling pathway in human vascular endothelial cells,” Cell Death & Disease, vol. 5, no. 12, pp. 1–13, 2014.
View at: Publisher Site | Google Scholar
N. Xia, A. Daiber, A. Habermeier et al., “Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 149–154, 2010.
View at: Publisher Site | Google Scholar
G. Spanier, H. Xu, and N. Xia, “Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4),” Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society, vol. 60, no. 11, pp. 111–116, 2009.
View at: Google Scholar
S. Kaga, L. Zhan, M. Matsumoto, and N. Maulik, “Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor,” Journal of Molecular and Cellular Cardiology, vol. 39, no. 5, pp. 813–822, 2005.
View at: Publisher Site | Google Scholar
S.-H. Juan, T.-H. Cheng, H.-C. Lin, Y.-L. Chu, and W.-S. Lee, “Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells,” Biochemical Pharmacology, vol. 69, no. 1, pp. 41–48, 2005.
View at: Publisher Site | Google Scholar
Z. Ungvari, Z. Bagi, A. Feher et al., “Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 299, no. 1, pp. H18–H24, 2010.
View at: Publisher Site | Google Scholar
H.-C. Chang, T.-G. Chen, Y.-T. Tai, T.-L. Chen, W.-T. Chiu, and R.-M. Chen, “Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells,” Journal of Cerebral Blood Flow and Metabolism, vol. 31, no. 3, pp. 842–854, 2011.
View at: Publisher Site | Google Scholar
T. Wallerath, G. Deckert, T. Ternes et al., “Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase,” Circulation, vol. 106, no. 13, pp. 1652–1658, 2002.
View at: Publisher Site | Google Scholar
N. S. Bryan, “Functional nitric oxide nutrition to combat cardiovascular disease,” Current Atherosclerosis Reports, vol. 20, no. 5, p. 21, 2018.
View at: Publisher Site | Google Scholar
F. Akar, O. Uludağ, A. Aydın et al., “High-fructose corn syrup causes vascular dysfunction associated with metabolic disturbance in rats: protective effect of resveratrol,” Food and Chemical Toxicology, vol. 50, no. 6, pp. 2135–2141, 2012.
View at: Publisher Site | Google Scholar
M. D. Nyby, K. Abedi, V. Smutko, P. Eslami, and M. L. Tuck, Vascular Angiotensin Type 1 Receptor Expression Is Associated with Vascular Dysfunction, Oxidative Stress and Inflammation in Fructose-Fed Rats, 2007.
J.-P. Huang, S.-C. Hsu, D.-E. Li, K.-H. Chen, C.-Y. Kuo, and L.-M. Hung, “Resveratrol mitigates high-fat diet-induced vascular dysfunction by activating the akt/eNOS/NO and Sirt1/ER pathway,” Journal of Cardiovascular Pharmacology, vol. 72, no. 5, pp. 231–241, 2018.
View at: Publisher Site | Google Scholar
Y. T. Wondmkun, “Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 13, pp. 3611–3616, 2020.
View at: Publisher Site | Google Scholar
M. M. Adeva-Andany, E. Ameneiros-Rodríguez, C. Fernández-Fernández, A. Domínguez-Montero, and R. Funcasta-Calderón, “Insulin resistance is associated with subclinical vascular disease in humans,” World Journal of Diabetes, vol. 10, no. 2, pp. 63–77, 2019.
View at: Publisher Site | Google Scholar
M. Ding, R. Feng, S. Y. Wang et al., “Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity,” Journal of Biological Chemistry, vol. 281, no. 25, pp. 17359–17368, 2006.
View at: Publisher Site | Google Scholar
N. Tena, J. Martín, and A. G. Asuero, “State of the art of anthocyanins: antioxidant activity, sources, bioavailability, and therapeutic effect in human health,” Antioxidants, vol. 9, no. 5, 2020.
View at: Publisher Site | Google Scholar
M. Banach, M. Wiloch, K. Zawada, W. Cyplik, and W. Kujawski, “Evaluation of antioxidant and anti-inflammatory activity of anthocyanin-rich water-soluble aronia dry extracts,” Molecules, vol. 25, no. 18, pp. 1–15, 2020.
View at: Publisher Site | Google Scholar
I. Serraino, L. Dugo, P. Dugo et al., “Protective effects of cyanidin-3-O-glucoside from blackberry extract against peroxynitrite-induced endothelial dysfunction and vascular failure,” Life Sciences, vol. 73, no. 9, pp. 1097–1114, 2003.
View at: Publisher Site | Google Scholar
A. M. Amorini, G. Lazzarino, F. Galvano, G. Fazzina, B. Tavazzi, and G. Galvano, “Cyanidin-3- O -β-glucopyranoside protects myocardium and erythrocytes from oxygen radical-mediated damages,” Free Radical Research, vol. 37, no. 4, pp. 453–460, 2003.
View at: Publisher Site | Google Scholar
T. Tsuda, F. Horio, K. Uchida, H. Aoki, and T. Osawa, “Dietary cyanidin 3-O-β-D-Glucoside-Rich purple corn color prevents obesity and ameliorates hyperglycemia in mice,” Journal of Nutrition, vol. 133, no. 7, pp. 2125–2130, 2003.
View at: Publisher Site | Google Scholar
M. Zhang, J. Ma, H. Bi et al., “Characterization and cardioprotective activity of anthocyanins from Nitraria tangutorum Bobr. by-products,” Food & Function, vol. 8, no. 8, pp. 2771–2782, 2017.
View at: Publisher Site | Google Scholar
J. Tan, Y. Li, D. X. Hou, and S. Wu, “The effects and mechanisms of cyanidin-3-glucoside and its phenolic metabolites in maintaining intestinal integrity,” Antioxidants, vol. 8, no. 10, pp. 1–16, 2019.
View at: Publisher Site | Google Scholar
S. Sivasinprasasn, R. Pantan, S. Thummayot, J. Tocharus, A. Suksamrarn, and C. Tocharus, “Cyanidin-3-glucoside attenuates angiotensin II-induced oxidative stress and inflammation in vascular endothelial cells,” Chemico-Biological Interactions, vol. 260, pp. 67–74, 2016.
View at: Publisher Site | Google Scholar
R. Pantan, J. Tocharus, A. Suksamrarn, and C. Tocharus, “Synergistic effect of atorvastatin and Cyanidin-3-glucoside on angiotensin II-induced inflammation in vascular smooth muscle cells,” Experimental Cell Research, vol. 342, no. 2, pp. 104–112, 2016.
View at: Publisher Site | Google Scholar
R. Pantan, J. Tocharus, M. Phatsara, A. Suksamrarn, and C. Tocharus, “Synergistic effect of atorvastatin and cyanidin-3-glucoside against angiotensin II-mediated vascular smooth muscle cell proliferation and migration through MAPK and PI3K/Akt pathways,” Archives of Pharmacal Research, pp. 1–12, 2016.
View at: Google Scholar
M. Y. Wu, C. J. Li, M. F. Hou, and P. Y. Chu, “New insights into the role of inflammation in the pathogenesis of atherosclerosis,” International Journal of Molecular Sciences, vol. 18, no. 10, 2017.
View at: Publisher Site | Google Scholar
G. L. Basatemur, H. F. Jørgensen, M. C. H. Clarke, M. R. Bennett, and Z. Mallat, “Vascular smooth muscle cells in atherosclerosis,” Nature Reviews Cardiology, vol. 16, no. 12, pp. 727–744, 2019.
View at: Publisher Site | Google Scholar
L. Dowsett, E. Higgins, S. Alanazi, N. A Alshuwayer, F. C Leiper, and J Leiper, “ADMA: a key player in the relationship between vascular dysfunction and inflammation in atherosclerosis,” Journal of Clinical Medicine, vol. 9, no. 9, pp. 1–17, 2020.
View at: Publisher Site | Google Scholar
S. Masi, M. Uliana, and A. Virdis, “Angiotensin II and vascular damage in hypertension: role of oxidative stress and sympathetic activation,” Vascular Pharmacology, vol. 115, pp. 13–17, 2019.
View at: Publisher Site | Google Scholar
L. Piqueras and M. J. Sanz, “Angiotensin II and leukocyte trafficking: new insights for an old vascular mediator. Role of redox-signaling pathways,” Free Radical Biology and Medicine, vol. 157, pp. 38–54, 2020.
View at: Google Scholar
K. M. Schmidt-Ott, S. Kagiyama, and M. I. Phillips, “The multiple actions of angiotensin II in atherosclerosis,” Regulatory Peptides, vol. 93, no. 1–3, pp. 65–77, 2000.
View at: Publisher Site | Google Scholar
A. Speciale, R. Canali, J. Chirafisi, A. Saija, F. Virgili, and F. Cimino, “Cyanidin-3-O-glucoside protection against TNF-α-induced endothelial dysfunction: involvement of nuclear factor-κb signaling,” Journal of Agricultural and Food Chemistry, vol. 58, no. 22, pp. 12048–12054, 2010.
View at: Publisher Site | Google Scholar
M.-M. Ma, Y. Li, X.-Y. Liu et al., “Cyanidin-3-O-Glucoside ameliorates lipopolysaccharide-induced injury both in vivo and in vitro suppression of NF-κB and MAPK pathways,” Inflammation, vol. 38, no. 4, pp. 1669–1682, 2015.
View at: Publisher Site | Google Scholar
A. Speciale, S. Anwar, and R. Canali, “Cyanidin-3-O-glucoside counters the response to TNF-alpha of endothelial cells by activating Nrf2 pathway,” Molecular Nutrition and Food Research, vol. 57, no. 11, pp. 1979–1987, 2013.
View at: Google Scholar
X. Luo, S. Fang, Y. Xiao et al., “Cyanidin-3-glucoside suppresses TNF-α-induced cell proliferation through the repression of Nox activator 1 in mouse vascular smooth muscle cells: involvement of the STAT3 signaling,” Molecular and Cellular Biochemistry, vol. 362, no. 1–2, pp. 211–218, 2012.
View at: Publisher Site | Google Scholar
D. Fratantonio, A. Speciale, D. Ferrari, M. Cristani, A. Saija, and F. Cimino, “Palmitate-induced endothelial dysfunction is attenuated by cyanidin-3-O-glucoside through modulation of Nrf2/Bach1 and NF-κB pathways,” Toxicology Letters, vol. 239, no. 3, pp. 152–160, 2015.
View at: Publisher Site | Google Scholar
D. Fratantonio, F. Cimino, and M. S. Molonia, “Cyanidin-3-O-glucoside ameliorates palmitate-induced insulin resistance by modulating IRS-1 phosphorylation and release of endothelial derived vasoactive factors,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1862, no. 3, pp. 351–357, 2017.
View at: Google Scholar
Z. Wang, M. Zhang, Z. Wang, Z. Guo, Z. Wang, and Q. Chen, “Cyanidin‐3‐ O ‐glucoside attenuates endothelial cell dysfunction by modulating miR ‐204‐5p/SIRT1 ‐mediated inflammation and apoptosis,” BioFactors, vol. 46, no. 5, pp. 803–812, 2020.
View at: Publisher Site | Google Scholar
Y. Wang, Y. Zhang, X. Wang, Y. Liu, and M. Xia, “Supplementation with cyanidin-3-O-β-Glucoside protects against hypercholesterolemia-mediated endothelial dysfunction and attenuates atherosclerosis in apolipoprotein E-deficient mice,” Journal of Nutrition, vol. 142, no. 6, pp. 1033–1037, 2012.
View at: Publisher Site | Google Scholar
H. Ruan, Y. Y. Zhan, J. Hou et al., “Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells,” Oncogene, vol. 36, no. 50, pp. 6906–6918, 2017.
View at: Publisher Site | Google Scholar
L. Liu, J. Liu, Z. Huang et al., “Berberine improves endothelial function by inhibiting endoplasmic reticulum stress in the carotid arteries of spontaneously hypertensive rats,” Biochemical and Biophysical Research Communications, vol. 458, no. 4, pp. 796–801, 2015.
View at: Publisher Site | Google Scholar
Y. Wang, Y. Liu, X. Du, H. Ma, and J. Yao, “The anti-cancer mechanisms of berberine: a review,” Cancer Management and Research, vol. 12, pp. 695–702, 2020.
View at: Publisher Site | Google Scholar
S. M. Ehteshamfar, M. Akhbari, J. T. Afshari et al., “Anti‐inflammatory and immune‐modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation,” Journal of Cellular and Molecular Medicine, vol. 24, no. 23, pp. 13573–13588, 2020.
View at: Publisher Site | Google Scholar
S. de Sarkar, D. Sarkar, A. Sarkar et al., “Berberine chloride mediates its antileishmanial activity by inhibiting Leishmania mitochondria,” Parasitology Research, vol. 118, no. 1, pp. 335–345, 2019.
View at: Publisher Site | Google Scholar
H. S. Bodiwala, S. Sabde, D. Mitra, K. K. Bhutani, and I. P. Singh, “Synthesis of 9-substituted derivatives of berberine as anti-HIV agents,” European Journal of Medicinal Chemistry, vol. 46, no. 4, pp. 1045–1049, 2011.
View at: Publisher Site | Google Scholar
H. M. Hussien, A. Abd-Elmegied, and D. A. Ghareeb, “Neuroprotective effect of berberine against environmental heavy metals-induced neurotoxicity and Alzheimer’s-like disease in rats,” Food and Chemical Toxicology, vol. 111, pp. 432–444, 2018.
View at: Google Scholar
H. Qiu, Y. Wu, Q. Wang et al., “Effect of berberine on PPARα-NO signalling pathway in vascular smooth muscle cell proliferation induced by angiotensin IV,” Pharmaceutical Biology, vol. 55, no. 1, pp. 227–232, 2017.
View at: Publisher Site | Google Scholar
S. Guan, B. Wang, W. Li, J. Guan, and X. Fang, “Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL,” The American journal of Chinese medicine, vol. 38, no. 6, pp. 1161–1169, 2010.
View at: Publisher Site | Google Scholar
L. Chi, L. Peng, X. Hu, N. Pan, and Y. Zhang, “Berberine combined with atorvastatin downregulates LOX-1 expression through the ET-1 receptor in monocyte/macrophages,” International Journal of Molecular Medicine, vol. 34, no. 1, pp. 283–290, 2014.
View at: Publisher Site | Google Scholar
M.-y. Gao, L. Chen, L. Yang, X. Yu, J.-p. Kou, and B.-y. Yu, “Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-κB/p65, Akt and MAPK pathway in THP-1 cells,” Pharmacological Reports, vol. 66, no. 3, pp. 480–484, 2014.
View at: Publisher Site | Google Scholar
Y.-S. Hsieh, W.-H. Kuo, T.-W. Lin et al., “Protective effects of berberine against low-density lipoprotein (LDL) oxidation and oxidized LDL-induced cytotoxicity on endothelial cells,” Journal of Agricultural and Food Chemistry, vol. 55, no. 25, pp. 10437–10445, 2007.
View at: Publisher Site | Google Scholar
R. Wang, Y. Zhang, L. Xu et al., “Protein inhibitor of activated STAT3 suppresses oxidized LDL-induced cell responses during atherosclerosis in apolipoprotein E-deficient mice,” Scientific Reports, vol. 6, Article ID 36790, 2016.
View at: Publisher Site | Google Scholar
R. X. Xu, X. C. Sun, C. Y. Ma et al., “Impacts of berberine on oxidized LDL-induced proliferation of human umbilical vein endothelial cells,” American Journal of Tourism Research, vol. 9, no. 10, pp. 4375–4389, 2017.
View at: Google Scholar
A. Takei, Y. Huang, and M. F. Lopes-Virella, “Expression of adhesion molecules by human endothelial cells exposed to oxidized low density lipoprotein Influences of degree of oxidation and location of oxidized LDL,” Atherosclerosis, vol. 154, no. 1, pp. 79–86, 2001.
View at: Publisher Site | Google Scholar
Z. Huang, X. Cai, S. Li et al., “Berberine-attenuated monocyte adhesion to endothelial cells induced by oxidized low-density lipoprotein via inhibition of adhesion molecule expression,” Molecular Medicine Reports, vol. 7, no. 2, pp. 461–465, 2013.
View at: Publisher Site | Google Scholar
J. P. Gaut and J. W. Heinecke, “Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis,” Trends in Cardiovascular Medicine, vol. 11, no. 3–4, pp. 103–112, 2001.
View at: Publisher Site | Google Scholar
C. Caliceti, P. Rizzo, R. Ferrari et al., “Novel role of the nutraceutical bioactive compound berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to lovastatin,” Nutrition, Metabolism, and Cardiovascular Diseases, vol. 27, no. 6, pp. 552–563, 2017.
View at: Publisher Site | Google Scholar
S.-J. Liu, C.-X. Yin, M.-C. Ding, Y.-Z. Wang, and H. Wang, “Berberine inhibits tumor necrosis factor-α-induced expression of inflammatory molecules and activation of nuclear factor-κB via the activation of AMPK in vascular endothelial cells,” Molecular Medicine Reports, vol. 12, no. 4, pp. 5580–5586, 2015.
View at: Publisher Site | Google Scholar
Y.-H. Wu, S.-Y. Chuang, W.-C. Hong, Y.-J. Lai, G.-J. Chang, and J.-H. S. Pang, “Berberine reduces leukocyte adhesion to lps-stimulated endothelial cells and vcam-1 expression both in vivo and in vitro,” International Journal of Immunopathology and Pharmacology, vol. 25, no. 3, pp. 741–750, 2012.
View at: Publisher Site | Google Scholar
Y. J. Ko, J. S. Lee, B. C. Park, H. M. Shin, and J. A. Kim, “Inhibitory effects of Zoagumhwan water extract and berberine on angiotensin II-induced monocyte chemoattractant protein (MCP)-1 expression and monocyte adhesion to endothelial cells,” Vascular Pharmacology, vol. 47, no. 2–3, pp. 189–196, 2007.
View at: Publisher Site | Google Scholar
M. Zhang, C.-M. Wang, J. Li et al., “Berberine protects against palmitate-induced endothelial dysfunction: involvements of upregulation of AMPK and eNOS and downregulation of NOX4,” Mediators of Inflammation, vol. 2013, Article ID 260464, 8 pages, 2013.
View at: Publisher Site | Google Scholar
F. Cheng, Y. Wang, J. Li et al., “Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans,” International Journal of Cardiology, vol. 167, no. 3, pp. 936–942, 2013.
View at: Publisher Site | Google Scholar
P. Puddu, G. M. Puddu, E. Cravero, S. Muscari, and A. Muscari, “The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases,” Canadian Journal of Cardiology, vol. 26, no. 4, pp. 140–145, 2010.
View at: Publisher Site | Google Scholar
K. R. Paudel, N. Panth, and D. W. Kim, “Circulating endothelial microparticles: a key hallmark of atherosclerosis progression,” Scientific, vol. 2016, Article ID 8514056, 9 pages, 2016.
View at: Publisher Site | Google Scholar
J. M. Hodgson and K. D. Croft, “Tea flavonoids and cardiovascular health,” Molecular Aspects of Medicine, vol. 31, no. 6, pp. 495–502, 2010.
View at: Publisher Site | Google Scholar
M. G.-P. Claudia Musial, “Beneficial properties of green tea catechins,” International Journal of Molecular Medicine, vol. 21, p. 1744, 2020.
View at: Google Scholar
J. Ouyang, K. Zhu, Z. Liu, and J. Huang, “Prooxidant effects of epigallocatechin-3-gallate in health benefits and potential adverse effect,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 9723686, 14 pages, 2020.
View at: Publisher Site | Google Scholar
E.-B. Byun, W. S. Kim, N.-Y. Sung, and E.-H. Byun, “Epigallocatechin-3-Gallate regulates anti-inflammatory action through 67-kDa laminin receptor-mediated tollip signaling induction in lipopolysaccharide-stimulated human intestinal epithelial cells,” Cellular Physiology and Biochemistry, vol. 46, no. 5, pp. 2072–2081, 2018.
View at: Publisher Site | Google Scholar
T. W. Kwak, S. B. Park, H. J. Kim, Y. I. Jeong, and D. H. Kang, “Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells,” OncoTargets and Therapy, vol. 10, pp. 137–144, 2017.
View at: Publisher Site | Google Scholar
B. A. Mir, S. Rasool, M. U. Rehman, I. Amin, and R. Ali, “Anticancer mechanistic insights of epigallocatechin-3-gallate, an active ingredient of green tea (camellia sinensis),” Plant and Human Health, Volume 2, vol. 2, pp. 139–157, 2019.
View at: Publisher Site | Google Scholar
M. Nikoo, J. M. Regenstein, and H. Ahmadi Gavlighi, “Antioxidant and antimicrobial activities of (-)-Epigallocatechin-3-gallate (EGCG) and its potential to preserve the quality and safety of foods,” Comprehensive Reviews in Food Science and Food Safety, vol. 17, no. 3, pp. 732–753, 2018.
View at: Publisher Site | Google Scholar
M. A. El-Missiry, A. I. Othman, M. R. El-Sawy, and M. F. Lebede, “Neuroprotective effect of epigallocatechin-3-gallate (EGCG) on radiation-induced damage and apoptosis in the rat hippocampus,” International Journal of Radiation Biology, vol. 94, no. 9, pp. 798–808, 2018.
View at: Publisher Site | Google Scholar
D. Bhatia, M. Bansal, S. Bhangu, G. Singh, and G. Singh, “Hepatoprotective effects of epigallocatachin gallate via mitochondrial permeability transition pore in paracetamol induced hepatotoxicity,” Plant Archives, vol. 19, pp. 2162–2167, 2019.
View at: Google Scholar
R. Kanlaya and V. Thongboonkerd, “Protective effects of epigallocatechin-3-gallate from green tea in various kidney diseases,” Advances in Nutrition, vol. 10, no. 1, pp. 112–121, 2019.
View at: Publisher Site | Google Scholar
Q. Zhang, L. Hu, L. Chen et al., “(−)-Epigallocatechin-3-gallate, the major green tea catechin, regulates the desensitization of β1 adrenoceptor via GRK2 in experimental heart failure,” Inflammopharmacology, vol. 26, no. 4, pp. 1081–1091, 2018.
View at: Publisher Site | Google Scholar
J. E. Chung, M. Kurisawa, Y.-J. Kim, H. Uyama, and S. Kobayashi, “Amplification of antioxidant activity of catechin by polycondensation with acetaldehyde,” Biomacromolecules, vol. 5, no. 1, pp. 113–118, 2004.
View at: Publisher Site | Google Scholar
G. Tipoe, T.-M. Leung, M.-W. Hung, and M.-L. Fung, “Green tea polyphenols as an anti-oxidant and anti-inflammatory agent for cardiovascular protection,” Cardiovascular & Haematological Disorders - Drug Targets, vol. 7, no. 2, pp. 135–144, 2012.
View at: Google Scholar
M. Sabetkar, S. Y. Low, N. J. Bradley, M. Jacobs, K. M. Naseem, and K. Richard Bruckdorfer, “The nitration of platelet vasodilator stimulated phosphoprotein following exposure to low concentrations of hydrogen peroxide,” Platelets, vol. 19, no. 4, pp. 282–292, 2008.
View at: Publisher Site | Google Scholar
Q. Meng, C. N. Velalar, and R. Ruan, “Regulating the age-related oxidative damage, mitochondrial integrity, and antioxidative enzyme activity in Fischer 344 rats by supplementation of the antioxidant epigallocatechin-3-gallate,” Rejuvenation Research, vol. 11, no. 3, pp. 649–660, 2008.
View at: Publisher Site | Google Scholar
L. Elbling, R.-M. Weiss, O. Teufelhofer et al., “Green tea extract and (−)‐epigallocatechin‐3‐gallate, the major tea catechin, exert oxidant but lack antioxidant activities,” The FASEB Journal, vol. 19, no. 7, pp. 1–26, 2005.
View at: Publisher Site | Google Scholar
G.-X. Li, Y.-K. Chen, Z. Hou et al., “Pro-oxidative activities and dose-response relationship of (−)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro,” Carcinogenesis, vol. 31, no. 5, pp. 902–910, 2010.
View at: Publisher Site | Google Scholar
H. Nakagawa, K. Hasumi, J. T. Woo, K. Nagai, and M. Wachi, “Generation of hydrogen peroxide primarily contributes to the induction of Fe(II)-dependent apoptosis in Jurkat cells by (-)-epigallocatechin gallate,” Carcinogenesis, vol. 25, no. 9, pp. 1567–1574, 2004.
View at: Publisher Site | Google Scholar
Z.-M. Wang, W. Gao, H. Wang et al., “Green tea polyphenol epigallocatechin-3-gallate inhibits TNF-a-induced production of monocyte chemoattractant protein-1 in human umbilical vein endothelial cells,” Cellular Physiology and Biochemistry, vol. 33, no. 5, pp. 1349–1358, 2014.
View at: Publisher Site | Google Scholar
W. S. Yang, H. Yu, J. J. Kim, M. J. Lee, and S.-K. Park, “Vitamin D-induced ectodomain shedding of TNF receptor 1 as a nongenomic action: D3 vs D2 derivatives,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 155, pp. 18–25, 2016.
View at: Publisher Site | Google Scholar
C. Zhang, “The role of inflammatory cytokines in endothelial dysfunction,” Basic Research in Cardiology, vol. 103, no. 5, pp. 398–406, 2008.
View at: Publisher Site | Google Scholar
W. S. Yang, S. Y. Moon, M. J. Lee, and S. K. Park, “Epigallocatechin-3-gallate attenuates the effects of TNF-α in vascular endothelial cells by causing ectodomain shedding of TNF receptor 1,” Cellular Physiology and Biochemistry, vol. 38, no. 5, pp. 1963–1974, 2016.
View at: Google Scholar
A. T. Reddy, S. P. Lakshmi, E. Maruthi Prasad, N. C. Varadacharyulu, and L. D. Kodidhela, “Epigallocatechin gallate suppresses inflammation in human coronary artery endothelial cells by inhibiting NF-κB,” Life Sciences, vol. 258, Article ID 118136, 2020.
View at: Publisher Site | Google Scholar
J. Shi, H. Deng, H. Pan, Y. Xu, and M. Zhang, “Epigallocatechin-3-gallate attenuates microcystin-LR induced oxidative stress and inflammation in human umbilical vein endothelial cells,” Chemosphere, vol. 168, pp. 25–31, 2017.
View at: Publisher Site | Google Scholar
J. Shi, M. Zhang, L. Zhang, and H. Deng, “Epigallocatechin-3-gallate attenuates microcystin-LR-induced apoptosis in human umbilical vein endothelial cells through activation of the NRF2/HO-1 pathway,” Environmental Pollution, vol. 239, pp. 466–472, 2018.
View at: Publisher Site | Google Scholar
R. C. Su, A. Lad, J. D. Breidenbach et al., “Assessment of diagnostic biomarkers of liver injury in the setting of microcystin-LR (MC-LR) hepatotoxicity,” Chemosphere, vol. 257, Article ID 127111, 2020.
View at: Publisher Site | Google Scholar
Z. Wang, G. Li, and Q. Wu, “Microcystin-LR exposure induced nephrotoxicity by triggering apoptosis in female zebrafish,” Elsevier, vol. 214, 2019.
View at: Publisher Site | Google Scholar
A. Al-hazmi, “N-acetylcysteine as a therapeutic extract for cardiac, lung, intestine and spleen injuries induced by microcystin-LR in mice,” Journal of King Saud University Science, vol. 32, no. 1, pp. 934–938, 2020.
View at: Publisher Site | Google Scholar
J. Shi, J. Zhou, and M. Zhang, “Microcystins induces vascular inflammation in human umbilical vein endothelial cells via activation of NF-B,” Mediators of Inflammation, vol. 2015, Article ID 942159, 7 pages, 2015.
View at: Publisher Site | Google Scholar
H. Y. Ahn, C. H. Kim, and T.-S. Ha, “Epigallocatechin-3-gallate regulates NADPH oxidase expression in human umbilical vein endothelial cells,” KOREAN JOURNAL OF PHYSIOLOGY and PHARMACOLOGY, vol. 14, no. 5, pp. 325–329, 2010.
View at: Publisher Site | Google Scholar
H. Y. Ahn and C. H. Kim, “Epigallocatechin-3-gallate regulates inducible nitric oxide synthase expression in human umbilical vein endothelial cells,” Laboratory Animal Research, vol. 27, no. 2, p. 85, 2011.
View at: Publisher Site | Google Scholar
H. J. Jang, S. D. Ridgeway, and J. A. Kim, “Effects of the green tea polyphenol epigallocatechin-3-gallate on high-fat diet-induced insulin resistance and endothelial dysfunction,” American journal of physiology. Endocrinology and metabolism, vol. 305, no. 12, pp. E1444–E1451, 2013.
View at: Publisher Site | Google Scholar
M. A. Potenza, F. L. Marasciulo, M. Tarquinio et al., “EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR,” American journal of physiology. Endocrinology and metabolism, vol. 292, no. 5, pp. E1378–E1387, 2007.
View at: Publisher Site | Google Scholar
D. Drozdz, J. Alvarez-Pitti, and M. Wójcik, “Obesity and cardiometabolic risk factors: from childhood to adulthood,” Nutrients, vol. 13, no. 11, pp. 1–20, 2021.
View at: Publisher Site | Google Scholar
C. Manrique, G. Lastra, and J. R. Sowers, “New insights into insulin action and resistance in the vasculature,” Annals of the New York Academy of Sciences, vol. 1311, no. 1, pp. 138–150, 2014.
View at: Publisher Site | Google Scholar
A. Rauf, M. Imran, I. A. Khan et al., “Anticancer potential of quercetin: a comprehensive review,” Phytotherapy Research, vol. 32, no. 11, pp. 2109–2130, 2018.
View at: Publisher Site | Google Scholar
M. Lesjak, I. Beara, and N. Simin, “Antioxidant and anti-inflammatory activities of quercetin and its derivatives,” Journal of Functional Foods, vol. 40, pp. 68–75, 2018.
View at: Google Scholar
L. R. Braga, L. M. Pérez, M. del v. Soazo, and F. Machado, “Evaluation of the antimicrobial, antioxidant and physicochemical properties of Poly(Vinyl chloride) films containing quercetin and silver nanoparticles,” Lebensmittel-Wissenschaft & Technologie, vol. 101, pp. 491–498, 2019.
View at: Google Scholar
D. Xu, M. J. Hu, Y. Q. Wang, and Y. L. Cui, “Antioxidant activities of quercetin and its complexes for medicinal application,” Molecules, vol. 24, no. 6, 2019.
View at: Publisher Site | Google Scholar
N. Suganthy, K. P. Devi, S. F. Nabavi, N. Braidy, and S. M. Nabavi, “Bioactive effects of quercetin in the central nervous system: focusing on the mechanisms of actions,” Biomedicine & Pharmacotherapy, vol. 84, pp. 892–908, 2016.
View at: Publisher Site | Google Scholar
J. Terao, “Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function,” Biochemical Pharmacology, vol. 139, pp. 15–23, 2017.
View at: Publisher Site | Google Scholar
L. Zhang, M. Dong, G. Guangyong Xu, fnm Yuan Tian, H. Tang, and Y. Wang, “Metabolomics reveals that dietary ferulic acid and quercetin modulate metabolic homeostasis in rats,” Journal of Agricultural and Food Chemistry, vol. 66, no. 7, pp. 1723–1731, 2018.
View at: Publisher Site | Google Scholar
W. Jiang, H. Zhang, J. Wu et al., “CuS@MOF-Based well-designed quercetin delivery system for chemo-photothermal therapy,” ACS Applied Materials & Interfaces, vol. 10, no. 40, pp. 34513–34523, 2018.
View at: Publisher Site | Google Scholar
R. Lin, J. Liu, W. Gan, and C. Ding, “Protective effect of quercetin on the homocysteine-injured human umbilical vein vascular endothelial cell line (ECV304),” Basic and Clinical Pharmacology and Toxicology, vol. 101, no. 3, pp. 197–202, 2007.
View at: Publisher Site | Google Scholar
W.-Y. Huang, L. Fu, C.-Y. Li, L.-P. Xu, L.-X. Zhang, and W.-M. Zhang, “Quercetin, hyperin, and chlorogenic acid improve endothelial function by antioxidant, antiinflammatory, and ACE inhibitory effects,” Journal of Food Science, vol. 82, no. 5, pp. 1239–1246, 2017.
View at: Publisher Site | Google Scholar
N. Suganya, E. Bhakkiyalakshmi, S. Suriyanarayanan, R. Paulmurugan, and K. M. Ramkumar, “Quercetin ameliorates tunicamycin-induced endoplasmic reticulum stress in endothelial cells,” Cell Proliferation, vol. 47, no. 3, pp. 231–240, 2014.
View at: Publisher Site | Google Scholar
B. Ozyel, G. le Gall, P. W. Needs, and P. A. Kroon, “Anti-inflammatory effects of quercetin on high-glucose and pro-inflammatory cytokine challenged vascular endothelial cell metabolism,” Molecular Nutrition and Food Research, vol. 65, no. 6, pp. 1–11, 2021.
View at: Publisher Site | Google Scholar
G. H. Werstuck, M. I. Khan, G. Femia et al., “Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model,” Diabetes, vol. 55, no. 1, pp. 93–101, 2006.
View at: Publisher Site | Google Scholar
R. A. DeFronzo, “Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links,” The Claude Bernard Lecture, vol. 53, no. 7, pp. 1270–1287, 2010.
View at: Google Scholar
X. Cai, L. Bao, Y. Ding, X. Dai, Z. Zhang, and Y. Li, “Quercetin alleviates cell apoptosis and inflammation via the ER stress pathway in vascular endothelial cells cultured in high concentrations of glucosamine,” Molecular Medicine Reports, vol. 15, no. 2, pp. 825–832, 2017.
View at: Publisher Site | Google Scholar
R. Tian, Z. Jin, L. Zhou, X.-P. Zeng, and N. Lu, “Quercetin attenuated myeloperoxidase-dependent HOCl generation and endothelial dysfunction in diabetic vasculature,” Journal of Agricultural and Food Chemistry, vol. 69, no. 1, pp. 404–413, 2021.
View at: Publisher Site | Google Scholar
S. Luangaram, U. Kukongviriyapan, P. Pakdeechote, V. Kukongviriyapan, and P. Pannangpetch, “Protective effects of quercetin against phenylhydrazine-induced vascular dysfunction and oxidative stress in rats,” Food and Chemical Toxicology, vol. 45, no. 3, pp. 448–455, 2007.
View at: Publisher Site | Google Scholar
O. E. Kale, O. Awodele, and A. J. Akindele, “Protective effects of acridocarpus smeathmannii (DC.) guill. & perr. Root extract against phenylhydrazine-induced haematotoxicity, biochemical changes, and oxidative stress in rats,” Biochemistry Insights, vol. 12, p. 117862641988324, 2019.
View at: Publisher Site | Google Scholar
U. Kukongviriyapan, K. Sompamit, P. Pannangpetch, V. Kukongviriyapan, and W. Donpunha, “Preventive and therapeutic effects of quercetin on lipopolysaccharide-induced oxidative stress and vascular dysfunction in mice,” Canadian Journal of Physiology and Pharmacology, vol. 90, no. 10, pp. 1345–1353, 2012.
View at: Publisher Site | Google Scholar
R. Kleemann, L. Verschuren, M. Morrison et al., “Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models,” Atherosclerosis, vol. 218, no. 1, pp. 44–52, 2011.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Nur Aqilah Kamaruddin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

594

Downloads

644

Citations